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                              ABSTRACT 
 
 
       Notch signaling is one of the pleotropic signaling pathway that plays key 
role in development as it promotes differentiation and tissue morphogenesis. In 
recent years it has been observed that this pathway along with many other 
developmental pathways is seen to be deregulated in different cancers. The role 
that is played by this pathway is highly context dependent in cancers that is in 
some cases it act as a tumor suppressor while as oncogenic in others. It is 
proved with its oncogenic role in all forms of breast cancer. We tried to assess 
the effects on this pathway in MDA MB-231 breast cancer cells after treatment 
with epigenetic modulators S-Adenosyl Methionine (SAM) and S-Adenosyl 
Homocysteine (SAH) in a time dependent manner for 0-48 hr. The expression 
of important notch receptor Notch-1 and downstream effector Hes-1 were 
shown to be down regulated after SAM  treatment but the SAH treatment 
upregulated them. This was accompanied by apoptotic induction in SAM 
treated cells in a more aggravated manner as compared to the SAH treated cells. 
From all these results we tentatively conclude that SAM treatment of invasive 
breast cancer cell line induces cell death in a notch dependent manner.
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                                       INTRODUCTION 
 
      The lifetime risk of developing breast cancer is about one in nine for women with 
around 1,41,000 new cases being diagnosed in the world wide each year. This has been 
proved recently as the worst and fatal breed of cancers in females. However, a significant 
decrease in the mortality since 1989 due to rigorous research, screening, specialization of 
care, and the widespread adoption of tamoxifen along with other effective anti-cancer 
therapeutics. More recently, number of Epigenetic therapeutics have emerged as new hopes 
for successful therapy of many cancers along with breast cancer working by altering the 
oncogenic epigenetic modifications that are one of the root causes of cancers. Despite this, 
there are still just short of 13,000 deaths each year due to breast cancer in western countries, 
suggesting that a much more in-depth understanding of the disease is required to improve 
treatment. Here in this study we have tried to test the anti-cancer efficacy of some epigenetic 
modulators like S-Adenosyl methionine (SAM), S- Adenosyl homocysteine (SAH) on breast 
cancer cell lines.  
       Notch signaling is an important embryonic signaling for development and tissue 
homeostasis and is deregulated in many human cancers. It is an important pathway for cell 
fate determination, stem cell maintenance and the initiation of differentiation in many tissues 
(Ye et al., 2012). Notch was discovered first in Drosophila melanogaster nearly a century ago 
pioneered the way to an ever-widening understanding of notch regulated or notch influenced 
cellular processes. The deregulation of such a pleiotropic pathway leads to several 
pathological conditions including cancer. Deregulated Notch signaling is well established in 
haematological malignancies and more recent studies have proved the importance of Notch 
activity in solid tumors. As the recent findings suggests it as an oncogene in some cancers but 
as a tumor suppressor in others. The role of Notch in solid tumors seems to be highly context 
dependent (Ranganathan et al., 2011).  
      Notch receptors are a class of single-pass trans-membrane proteins encoded by the Notch 
genes which can be activated by the binding of a family of compatible ligands. Four 
Notch receptors have been identified till date in mammals, including human, described 
as Notch-1-4. The mammalian canonical notch ligands are total five in number and divided 
into two groups denoted as Delta-like (Delta-like 1, Delta-like 3, and Delta-like 4) or Serrate-
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like ligands, known as Jagged-1 and Jagged-2. All the four Notch receptors are very similar 
in structure except some minute differences in their extracellular and intra-cytoplasmic 
domains. The fine structure of extracellular domains of Notch contains a number of repeated 
copies of an epidermal growth factor (EGF)-like motif that are involved in ligand interaction. 
The Notch-1 and Notch-2 proteins have 36 sequenced repeats of EGF-like domain and 
the Notch-3 and Notch-4 contain 34 and 29 EGF-like repeats respectively. In the amino-
terminal the sequence of EGF-like repeats are followed by a group of cysteine rich Notch 
Lin12 repeats (N/Lin12) which facilitates  interactions of the extracellular and the 
intracellular domains. In the cytoplasmic region of Notch there exists domains like a 
Recombination Signal-Binding Protein 1 for J-kappa (RBP-J)-association molecule (RAM) 
domain, ankyrin (ANK) repeats, nuclear localization signals (NLS), a trans-activation domain 
(TAD), and a region rich in proline, glutamine, serine, and threonine residues (PEST) 
sequence. It is commonly known that the ANK repeats are necessary and sufficient for 
Notch activity while the PEST sequence is involved in Notch protein turnover. 
 
Fig.1 (A) Structure of Notch receptors (1-4) and ligands (Jagged-1, 2, Dll-1, 3, 4 (B) The 
Canonical notch Signaling Pathway [Figure Ref. from, “Wang, Z., Li, Y., Kong, D., Ahmad, A., 
Banerjee, S., & Sarkar, F. H. (2010). Cross-talk between miRNA and Notch signaling pathways in 
tumor development and progression. Cancer Lett, 2009”] 
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     The cytoplasmic region of the receptor conveys the signal to the nucleus. The 
Notch ligands possess multiple EGF-like repeats in their extracellular domain and a cysteine-
rich region (CR) in serrate type while these are devoid in Delta. The Jagged-1 and Jagged-2 
bears almost twice the numbers of EGF-like repeats compared to Delta. Notch signaling is 
activated by the ligand dependent way where the neighboring cells secrete the ligand. A 
series of proteolytic cleavages are underway by the metalloproteases, tumor necrosis factor-
α-converting enzyme (TACE) and γ-secretase complex (comprised of presenilin-1/2, 
nicastrin, Pen- 2, and Aph-1) when the signaling is active. TACE sheds the first blood 
making the first cleavage that leads to cleave the receptor in the extracellular domain. The 
trans-endocytosis of the released extracellular domain takes place by the ligand 
expressing cell. The second cut is usually caused by the γ-secretase complex releases the 
Notch intracellular domain (NICD) into the cytoplasm, which can subsequently translocate 
into the nucleus because of the presence of nuclear localization signals located within it. 
Blocking the γ-secretase function prevents the cleavage of the Notch receptor thereby 
stopping the Notch signal transduction. The γ-secretase inhibitors (GSI) could be potential 
candidates for the treatment of human malignancies. When the NICD is absent the 
transcription of Notch target genes is blocked with a repressor complex mediated by the CSL 
(C protein binding factor 1/Suppressor of Hairless/Lag-1). When NICD comes in to the 
nucleus, it forms an active transcriptional complex by displacing the histone deacetylase–
corepressor complex and recruiting the protein mastermind like1 (MAML1) and histone 
acetyl transferases (HAT) to the CSL complex and leads to its conversion from a 
transcriptional repressor into a transcription activator complex. A few important Notch target 
genes that have been established includes Hes (Hairy enhance of split) family, Hey 
(Hairy/ enhancer of spit related with YRPW motif), nuclear factor-kappa B (NF- κB), 
vascular growth factor receptor (VEGF), mammalian target of rapamycin (mTOR), cyclin 
D1, c-myc, p21, p27, Akt, etc. All of these candidates have been proved with their foul play 
in tumor development and progression (Wang et al., 2010).  
      The aberrations in Notch signaling are significantly correlated to the happening and 
development of many cancers along with many other developmental pathways (Kar et al., 
2012). The expression levels of genes associated with the Notch signaling pathway are 
correlated with tumor pathology and the degree of differentiation. Notch1 and Notch2 gene 
expression are correlated with tumor pathology type and degree of differentiation. (Jin et al., 
2012). In some tumor the tumor suppressor genes are silenced partly through deacetylation of 
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promoter regions and the treatment with HDAC inhibitors therefore contributes to re-
expression of these genes. The whole phenomenon is known to be mediated by the notch 
signaling components in various solid tumors. Still an in-depth understanding of the 
underlying molecular mechanisms behind the mode of action of HDAC inhibitors on tumour 
cells remains obscure .In another mechanism the bHLH protein Hairy and Enhancer of Split-
1(Hes-1), that functions as a negative regulator of transcription, is one direct and important 
transcriptional target of Notch signaling (Stockhausen et al., 2005).Emerging reports signifies 
that Notch signaling pathway is one of the convicts for the drug-resistant tumor phenotype. 
The down-regulation of Notch pathway could be an important therapeutic approach for 
induction of drug sensitivity and increased inhibition of cancer cell growth, invasion, and 
metastasis (Wang et al., 2010). 
1.1 Epigenetics and cancer 
 
      Epigenetics can be described as a stable alteration in gene expression potential that takes 
place during development and cell proliferation, without any change in gene sequence. DNA 
methylation is one of the most commonly occurring epigenetic events in the mammalian 
genome. This change, though heritable, is reversible, making it a therapeutic target. 
Epigenetics has evolved as a rapidly developing area of research. Recent studies have shown 
that epigenetics plays an important role in cancer biology, viral infections, activity of mobile 
elements, somatic gene therapy, cloning, transgenic technologies, genomic imprinting, 
developmental abnormalities, mental health, and X-inactivation. DNA methylation is an 
important regulator of gene transcription, and its role in carcinogenesis has been a topic of 
considerable interest in the last few years. Alterations in DNA methylation are common in a 
variety of tumours as well as in development. Of all epigenetic modifications, hyper 
methylation, which represses transcription of the promoter regions of tumours suppressor 
genes leading to gene silencing, has been most extensively studied (Patra et al., 2008) . 
 
      DNA methylation is a covalent chemical modification, resulting in the addition of a 
methyl (CH3) group at the carbon 5 position of the cytosine ring. Even though most cytosine 
methylation occurs in the sequence context 5‟-CG-3‟ (also called the CpG dinucleotide), 
some also involves CpA and CpT dinucleotides. DNA is made up of four bases, thus there are 
16 possible dinucleotide combinations that can occur. Therefore the CpG-dinucleotide should 
occur with a frequency of approximately 6%.However, the actual presence is only 5% to10% 
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of its predicted frequency. This CpG suppression may be related to the hyper mutability of 
methylated cytosine. The human genome is not methylated uniformly and contains regions of 
unmethylated segments interspersed by methylated regions. In contrast to the rest of the 
genome, smaller regions of DNA, called “CpG islands”, ranging from 0.5 to 5 kb and 
occurring on average every 100 kb, have distinctive properties. These regions are 
unmethylated, GC rich (60% to 70%), have a ratio of CpG to GpC of at least 0.6, and thus do 
not show any suppression of the frequency of the dinucleotide CpG. Approximately half of 
all the genes in humans have CpG islands and these are present on both housekeeping genes 
and genes with tissue specific patterns of expression. DNA methylation is brought about by a 
group of enzyme known as the “DNA methyltransferases (DNMTs)”. The DNMTs known to 
date are DNMT1, DNMT1b, DNMT1o, DNMT1p, DNMT2, DNMT3A, and DNMT3B with 
its isoforms (Patra et al., 2002) . 
 
 
  
FIG 2. (A) Maintenance and (B) de novo DNMTS methylate DNA. DNMT1 binds methyl groups 
to the hemimethylated DNA during replication, whereas DNMT3A and DNMT3B can add methyl 
groups to CpG dinucleotides of unmethylated DNA. 
  
                                                                                                                         Introduction 2013 
 
 
6 
1.1.1   DNA methylation and gene regulation 
  
      The regulation of eukaryotic gene expression is a complex process. Transcription 
initiation is a highly controlled and integrated event that involves cis-acting and trans-acting 
factors. The cis-acting elements are DNA sequences that act as the substrate for the trans-
acting factors, and the DNA in the vicinity is prepared for transcription. Increased 
methylation in the promoter region of a gene leads to reduced expression, whereas 
methylation in the transcribed region has a variable effect on gene expression. Several 
mechanisms have been proposed to account for transcriptional repression by DNA 
methylation. The first mechanism involves direct interference with the binding of specific 
transcription factors to their recognition sites in their respective promoters. Several 
transcription factors, including AP-2, c-Myc/Myn, the cyclic AMP-dependent activator 
CREB, E2F, and NF-kB, recognize sequences that contain CpG residues, and binding of each 
has been shown to be inhibited by methylation. 
 
      The second mode of repression involves a direct binding of specific transcriptional 
repressors to methylated DNA. The DNA methylation signals are analyzed by the methyl-
CpG–binding proteins, the target being the 5-methylated CpG sequence. MeCP1 and MeCP2 
were the first two protein complexes identified. However, several new proteins have now 
been identified. They include MBD1, MBD2, MBD4, and Kaiso. MeCP1, MBD1, MBD2, 
and MBD4 bind to 5mCpG through a motif called the methyl CpG binding domain (MBD). 
Kaiso, however, is different in mechanism, as it binds through a zinc finger motif. MBD4 is 
associated with DNA repair, whereas MBD1, MBD2, MeCP2, and Kaiso have been shown to 
repress transcription both in vitro and in cell culture assays by interacting with histone 
deacetylase complexes. DNA methylation can also affect histone modifications and 
chromatin structure, which, in turn, can alter gene expression. The underlying patterns of 
methylated cytosines are important in guiding histone deacetylation to certain residues. At 
present, there are five known proteins that have the methyl-CpG–binding domain, and four of 
these (MeCP2, MBD1, MBD2, and MBD3) are implicated in transcriptional repression. 
Three of these (MeCP2, MBD2, and MBD3) are in complexes (MeCP-2, MeCP-1 and Mi-2, 
respectively) that contain histone deacetylase. Studies of methylated transfected genes 
containing binding sites for all four of these methyl-binding proteins have shown at least 
partial abrogation of transcriptional repression by treatment with the histone deacetylase 
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inhibitor, Trichostatin A. Earlier it was suggested that histone modification was secondary to 
DNA methylation, but recent studies on fungus revealed that histone modification can on its 
own commence the process of DNA methylation. The methylation of lysine in histones by 
specific histone methylases is also implicated in changes in chromatin structure and gene 
regulation. A zone of deacetylated histone H3 and methylation of histone H3 at lysine 9 
surrounds a hypermethylated, silenced hMLH1 promoter, which, when unmethylated and 
active, is associated with acetylated H3 and methylation of histone H3 at lysine 4 position. 
Inhibiting DNA methyltransferases, but not histone deacetylases, leads initially to promoter 
demethylation, followed by gene re-expression, and finally to complete histone code reversal. 
 
 
FIG 3. Mechanism of DNA methylation proposed by Reither et al. (2003) and S K Patra et al. 
(2008) Cancer and Metast Rev 
 
1.1.2 Role of DNA methylation in carcinogenesis 
 
       Earlier it was thought that normal cells become progressively transformed to malignant 
cells as a consequence of damage to the genome, which could be a gain, loss, or mutation of 
the genetic information. These events cause critical loss of gene activity and thereby 
predispose to cancer. DNA methylation can modify the gene activity without changing the 
gene sequence and has been proposed as one of the two hits in “Knudson’s two hits 
hypothesis” for oncogenic transformation. Methylation changes have been implicated in 
tumorigenesis. DNA methylation in cancer has become the topic of intense investigation. As 
compared with normal cells, the malignant cells show major disruptions in their DNA 
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methylation patterns. Hypomethylation usually involves repeated DNA sequences, such as 
Long Interspersed Nuclear Elements (LINE), whereas Hypermethylation involves CpG 
islands. Both hypo- and hypermethylation play a prominent role in carcinogenesis, and their 
contribution shows scarcely defined boundaries. It has long been known that in cancer cells 
both alterations co-exist: malignant tumors show global hypomethylation and regional 
hypermethylation. Whether one must precede the other or whether both should start at the 
same time remains to be elucidated. In terms of carcinogenesis, the first observations in fact 
were done on hypomethylation (Feinberg et al., 1983); later, the discovery of regional 
hypermethylation as a means to silence the tumor suppressor genes expression gained the 
most attention (de Bustros et al., 1988). 
 
1.1.3 Hyper-methylation and gene silencing 
 
      Observations that tumour suppressor genes can be inactivated not only through structural 
changes (mutation, deletion) but also by lack of expression due to promoter hypermethylation 
positioned tumour suppressor gene epigenetic silencing as a well-established oncogenic 
process (Laird et al., 1994). The first suppressor gene known to be hypermethylated and 
silenced was Retinoblastoma (RB) (Greger et al., 1989), which was followed by multiple 
publications describing similar findings for a variety of tumour suppressor genes, among 
them p16, MLH1, VHL, and E-cadherin (Santini et al.,  2001).   
    To date, numerous genes have been found to undergo hypermethylation in cancer. The 
genes that are susceptible are the genes involved in cell cycle regulation (p16INK4a, 
p15INK4a, Rb, p14ARF) genes associated with DNA repair (BRCA1, MGMT), apoptosis 
(DAPK, TMS1), drug resistance, detoxification, differentiation, angiogenesis, and metastasis. 
Although certain genes such as RASSF1A and p16 are commonly methylated in a variety of 
cancers, other genes are methylated in specific cancers. One example is the GSTP1 gene, 
which is hypermethylated in more than 90% of prostate cancers but is largely unmethylated 
in acute myeloid leukaemia (Lee et al., 1994; Melki et al., 1999). The mechanisms involved 
in targeting of methylation to specific genes in cancer remain to be determined. In one report, 
the leukaemia-promoting PMLRAR fusion protein induced gene hypermethylation and 
silencing by recruiting DNA methyltransferases to target promoters (Di Croce et al., 2002). 
Interestingly, retinoic acid treatment induced promoter demethylation, gene re-expression, 
and reversion of the transformed phenotype. Many tumors show some kind of 
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hypermethylation of one or more genes. One of the most detailed studies was conducted on 
lung cancer, and more than 40 genes were found to have some degree of alteration in DNA 
methylation patterns. Of the various genes studied, the commonly hypermethylated ones 
include RARβ2, RASSF1A, CDNK2A, CHD13, and APC (Tsou et al., 2002). 
Hypermethylation results in loss of expression of a variety of genes critical in the 
development of breast cancer. These include steroid receptor genes, cell adhesion genes, and 
inhibitors of matrix metalloproteinases (Yang et al., 2001). Among the genes commonly 
hypermethylated in breast cancer are the p16NK4A, estrogen receptor (ER) alpha, the 
progesterone receptor (PR), BRCA1, GSTP1, TIMP-3, and E-cadherin. The steroid receptor 
genes, ER and PR, have long been associated with breast cancer. Methylation studies of these 
have shown that the ER gene has a CpG island in its promoter and first exon areas (Yang et 
al., 2001). The ER gene is unmethylated in normal cells and in ER-positive cell lines but 
shows a high degree of methylation in more than half of primary cancers. The BRCA1 gene, 
located at chromosome 17q21, is one of the more commonly associated genes in breast 
cancer, and the protein product is reduced or absent. DNA methylation has been proposed as 
one of the causes of its inactivation (Catteau et al., 2002). 
 
      Whether gene promoter hypermetylation is the cause or consequence for the tumor 
suppressor gene silencing is still a matter of controversy; nevertheless, these views are not 
mutually exclusive. DNA methylation is causal has been shown by the ability of diverse 
pharmacologic compounds and molecular techniques to reactivate gene expression upon 
inhibition of DNA methylation in cancer cells (Szyf et al., 2003). On the other hand, other 
findings suggest that hypermethylation-induced gene silencing could be secondary to changes 
that determine gene expression, such as chromatin modification, so that methylation helps to 
maintain the silenced status of the gene. Strong support for the second view came from 
experiments showing that methylation of histone H3 lysine 9–that is, chromatin modification 
occurred, along with re-silencing of p16 in absence of DNA methylation in cells in which p16 
had previously been activated by knocked out of DNA methyltransferase (Bachman, 2003) 
and by data demonstrating p16 silencing in mammary epithelial cells that had escaped 
senescence and had demethylated the promoter (Clark et al., 2002).  
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1.1.4 Hypomethylation and gene activation 
 
      Tumour cells have global DNA hypomethylation that can be as high as 60% less than 
their normal counterparts (Goelz et al., 1985). It is common in solid tumours such as 
metastatic hepatocellular cancer, (Lin et al., 2001) in cervical cancer, (Kim et al., 1994) 
prostate tumours (Bedford et al., 1987), and also in hematologic malignancies such as B-cell 
chronic lymphoblastic leukaemia (Ehrlich, 2002). The global hypomethylation seen in a 
number of cancers, such as breast, cervical, and brain, show a progressive increase with the 
grade of malignancy (Ehrlich, 2002). This hypomethylation occurs mainly in the body of 
genes (coding regions and introns), as well as in pericentromeric regions of chromosomes 
rich in repetitive DNA sequences (Ehrlich, 2002). Interestingly, hypomethylation is 
progressive from premalignant conditions to fully developed malignancies (Dunn, 2003). The 
main mechanisms put forward in attempting to explain cancer causation by hypomethylation 
include chromosome instability and reactivation of transposable elements and/or 
inappropriate gene activation (Gamma-Sosa et al., 1983).  (Oncogenes such as cMYC and H-
RAS75).  There are two pieces of convincing evidence linking hypomethylation with 
chromosomal instability. The congenital disorder ICFs syndrome immunodeficiency, 
chromosomal instability, and facial anomalies caused by mutations at DNMT3b demonstrates 
loss of methylation in classical satellite DNA and mitogen-inducible formation of bizarre 
multiracial chromosomes that contain arms from chromosomes 1 and 16 (Eden A et al., 
2003). This disorder, however, is not associated with cancer, but common somatic tumors 
such as breast, ovarian, and other epithelial tumors commonly have unbalanced chromosomal 
translocations with breakpoints in the  pericentromeric DNA of chromosomes 1 and 16 
(Hansen RS et al., 1999). In mouse models with an inactivated allele of NF1 and p53 genes, 
introduction of a hypomorphic DNMT1 allele caused a 2.2-fold increase in LOH frequency 
(Narayan A et al., 1998). Finally, some reports have stressed the fact that many CpG islands 
are normally methylated in somatic tissues (Strichman-Almashanu LZ, 2002), and that 
demethylation could lead to activation of nearby genes such as HRAS. Indeed, experimental 
demonstration exists that hypomethylation leads to activation of genes important for cancer 
development, including promoter CpG demethylation and overexpression of 14-3-3sigma, 
maspin, heparanase, and S100A4 in several tumor types (Ogishima T et al., 2005; Sato N et 
al., 2003; Akiyama Y et al., 2003).  
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      The question here is whether over-expression was indeed caused by hypomethylation or 
whether promoters are hypomethylated secondary to its high transcriptional activity. There 
are data showing that the sole hypomethylation as achieved by pharmacologic means is not 
sufficient to activate gene expression. In this context, some genes are not permisive for 
expression; this means that despite the fact that methylation is relieved the necessary 
ancillary factors to activate transcription are not present. Others are permissive and therefore 
reactivated by demethylation, whereas for others hypomethylation does not affect their levels 
of  expression but can be overexpressed due to activation of signalling pathways known to 
activate them (Karpf  AR et al., 2004). 
1.1.5 Histone Methylation and Cancer 
 
      The transfer of methyl group from its cofactor SAM (S Adenosyl Methionine) to the 
amino acids basically arginine and lysine of histone protein is called as Methylation. 
Methylation occurs in two levels that is in the DNA level and histone level and therefore 
known as DNA Methylation and Histone Methylation. The enzymes those are involved in 
DNA Methylation are DNMT (DNA Methyltransferase) and histone Methylation is HMT 
(Histone Methyltransferase). Methylation works as gene silencing as a result of which they 
repress the transcription process. Methylation in addition is of two types i.e. genome wide 
hypomethylation and regional hypermethylation. Histone methylation takes place at lysine 
and arginine residues. Methylation of lysine takes place at H3K4, H3K36, H3K79, H3K9, 
H3K27 and H4K20 position. Arginine methylation of histone takes place at H3R2, H3R17 
and H3R26 etc. 
 
2. Epigenetic Modulators: SAM and SAH 
 
2.1 S-Adenosyl Methionine (SAM) 
 
      S-Adenosyl methionine (ademetionine, AdoMet, SAM, SAMe, SAM-e) is a common co-
substrate involved in methyl group transfers. SAM was first discovered in Italy by G. L. 
Cantoni in 1952. It is made from adenosine triphosphate (ATP) 
and methionine by methionine adenosyltransferase (EC 2.5.1.6). Transmethylation, trans-
sulfuration, and aminopropylation are the metabolic pathways that use SAM. Although 
these anabolic reactions occur throughout the body, most SAM is produced and consumed in 
the liver. The methyl group (CH3) attached to the methionine sulfur atom in SAM is 
chemically reactive. This allows donation of this group to an acceptor substrate in trans 
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methylation reactions. More than 40 metabolic reactions involve the transfer of a methyl 
group from SAM to various substrates, such as nucleic acids, proteins, lipids and secondary 
metabolites. In bacteria, SAM is bound by the SAM riboswitch which regulates genes 
involved in methionine or cysteine biosynthesis. 
  
        
 
             Fig 4. Molecular structure of S-Adenosyl Methionine (SAM) 
 
2.2 S-Adenosyl Homocysteine 
 
     S-Adenosyl-L-homocysteine (SAH) is an amino acid derivative used in several metabolic 
pathways in most organisms. It is an intermediate in the synthesis of cysteine and adenosine. 
SAH is formed by the demethylation of S-adenosyl-L-methionine (SAM). 
 
 
     
  
                      Fig 5. Molecular structure of S-Adenosyl Homocysteine (SAH)
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                               REVIEW OF LITERATURE 
 
1. Notch signaling in cancers  
     The expression of the first two Notch receptors Notch1 and Notch2 have important role in 
tumor pathology, type casting and degree of differentiation. In the tumors expressing high 
levels of Notch2 and JAG1 are correlated with a significantly better prognosis in comparison 
to patients expressing stunted levels of Notch2 and JAG1 (Jin et al., 2012).Involvement of 
Notch signaling is variedly reported in different cancers.  
      Notch expression is not yet fully determined in hepatoblastoma as most of the genes 
closed to Notch signaling pathway show abridged expression. But in another study of 
hepatoblastoma, NOTCH1 along with DLL1, CD44, FZD2, GLI1, IL17B, LMO2, LOR, 
PAX5, PT-CRA, SH2D1A and WISP1 were shown to be upregulated and contributed to 
invasiveness but DLL1, HEY1, DTX1, HDAC1, NOTCH2 and JAG1  were not found to be 
methylated there (Aktas et al., 2010). Within Kaposisarcoma (KS) lesions, the KSHV-
infected spindle cells showed features compatible with KSHV-induced EndMT and involves 
a complex phenotype of endothelial and mesenchymal properties with Notch activity, and 
nuclear ZEB1 expression. This proves Notch signaling inhibitors could be effective in KS 
treatment (Gasperini et al., 2012). The active role of Notch in HPV-mediated transformations 
in different gynecological cancers is dose dependent and correlated to a variation in activator 
protein, AP-1 expression (Henken et al., 2012). Delta-like ligand 4 (DLL4) is one of the 
major notch inducing ligand and its expression is vividly associated with poor prognosis for 
surgically resected Pancreatic ductal adeno-carcinoma (PDAC), advanced tumor stage and 
lymph node metastasis (Chen et al., 2012). In oral squamous cell carcinoma tumor growth is 
promoted by Notch-1 along with β-catenin (component of Wnt signaling), ΔNp63 
(proliferation marker and trans-membrane receptor) expression. The same study also aims to 
investigate the interaction between β-catenin and ΔNp63 in oral cancer(Ravindran and 
Devaraj, 2012). The down regulated expression of Notch 1 was related to invasion and 
differentiation in oral carcinoma cells. In some lingual squamous carcinoma cell Notch1 
down-regulation could be correlated with the expression of matrix metallo-proteinase 
(MMP)-2 and MMP-9 to promote inhibition of invasion and metastasis (Yu et al., 2012a). 
                                                                                                             Review of Literature 2013 
 
 
14 
ER-Notch signaling along with the GPR30-PI3K/AKT signaling mediates regulation of 
proliferation in nuclear ER-positive endometrial cancer cells (Wei et al., 2012). The down-
regulation of Notch3 sufficiently forces Rhabdomyosarcoma (RMS) cells to complete a 
correct full myogenic program thus provides evidence that it contributes to their malignant 
phenotype partially through HES1 sustained expression, (Raimondi et al., 2012). 
Deregulation of NUMB-mediated suppression of NOTCH1 by TNFα/IKKα- associated 
FOXA2 inhibition likely contributes to inflammation-mediated cancer pathogenesis in 
hepatocellular carcinoma (Liu et al., 2012). Notch2 and JAG1 expression levels are 
correlated with survival in colorectal cancers (Jin et al., 2012). Kaposi's sarcoma-associated 
herpes-virus (KSHV) activated Notch-induced transcription factors Slug and ZEB1, and 
canonical Notch signaling is pivotal for KSHV-induced Endothelial-mesenchymal Transition 
(EndMT). So Notch inhibitors together with the currently used chemotherapeutic drugs to 
improve the outcome of Osteosarcoma (OS) treatment (Ma et al., 2013). The link between the 
anti-apoptotic pathways of Notch, Wnt and Hedgehog and bone marrow stromal cells in 
chronic lymphoblastic leukemia (CLL) has been pointed out only recently. A number of anti-
cancer drugs, including γ-secretase inhibitors, Cyclopamine and Quercetin, were reported to 
block Notch along with Wnt, and Hedgehog anti-apoptotic signaling pathways respectively in 
these cancers (Seke Etet et al., 2012). Overexpressed DLL4 on neoplastic cells is shown to 
enhance chemo resistance via angiogenesis-dependent/independent mechanisms in pancreatic 
ductal adeno-carcinoma PDAC(Kang et al., 2013). The matrix cellular protein, secreted 
protein acidic and rich in cysteine (SPARC), is known to inhibit proliferation and migration 
of endothelial cells stimulated by growth factors. In a recent report pSPARCCM- suppressed 
expression of growth factors was shown to be mediated by inhibition of the Notch signaling 
pathway, and cells cultured on conditioned medium from tumor cells overexpress both Notch 
intracellular domain (NICD-CM) and SPARC resumed the pSPARCCM- suppressed 
capillary tube formation and growth factor expression in vitro (Gorantla et al., 2013).  
       Notch signaling aggravates the efficacy of some drugs in some cancers and also is 
activated by some drugs and in many ways can contribute to targeted cancer therapy. Notch2 
activation impedes inhibitory effect of Benzene isothiocyanate (BITC) on cell migration in 
human breast cancer cells (Kim et al., 2012). Withaferin A (WA) one small-molecule 
constituent of the ayurvedic medicine plant Withania somnifera with efficacy against cultured 
and xenografted human breast cancer cells treatment activates Notch2 and Notch4, which 
impede inhibitory effect of WA on breast cancer cell migration (Lee et al., 2012). 
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Organization of tumor cells into capillary like structures (CLS) is known as vasiculogenic 
mimicry (VM). VM regulated by Notch signaling may present a novel target in melanoma 
therapy (Vartanian et al., 2012). Curcumin is a potent inhibitor of esophageal cancer growth 
that targets the Notch-1 activating gamma-secretase complex proteins. This suggests that 
Notch signaling is pivotal in oesopageal cancer growth and its inhibition is a novel 
mechanism of action for curcumin during therapeutic intervention in esophageal cancers 
(Subramaniam et al., 2012). The expression of DLL4 is associated with reduced radio-
resistance, presumably by reducing hypoxia and improving chemotherapy accessibility. 
Using the combination of CD31 and DLL4 staining, a classification is suggested so that 
HNSCCs are categorized in sub-groups to be targeted by different anti-angiogenic and 
hypoxia targeting agents (Koukourakis et al., 2012). In human myeloma cells, RT-PCR and 
flow-cytometry analysis has revealed that JAG2, the major Notch ligand, is often expressed 
by CD138+ primary cells and recent out comes indicate that spontaneous clonogenic growth 
of myeloma cells requires the expression of JAG2 (Chiron et al., 2012).  
 
 
 
 
 
 
 
 
 
 
        
 
      Fig 6.  Aberrant Notch signaling in cancers showing context dependent properties 
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      Correlation of Notch1, 2, 3, Jagged1, cMET, and pMAPK, has shown their correlation to 
clinicopathologic characteristics and prognostic utility for prediction of patient outcome 
(Krikelis et al., 2012).The Notch repressor Numbl negatively regulates glioma cell migration 
and invasion by abrogating TNF receptor-associated factor 5, TRAF5-induced activation of 
NF-κB this suggests that Notch inhibitors may be best used in combination with other agents 
or therapy. (Yu et al., 2012b). Down-regulated Notch1 is shown to be an effective approach 
to inactivating Snail/E-cadherin by regulating the COX-2 enzyme responsible for 
inflammation and pain results in inhibition of the invasion and migration of Hepatocellular 
carcinoma cells (HCC) cells. Here the inhibitory effects of down regulated Notch1 on cell 
invasion and migration were found to be  independent of apoptosis (Zhou et al., 2012). In 
Nasopharyngeal carcinoma (NPC) patients high expression level of DLL4 ligand serves as an 
independent predictor of poor prognosis (Zhang et al., 2013). Notch has an important role in 
lung cancer and treatment with GSI after radiation can significantly enhance radiation 
mediated tumor cytotoxicity (Mizugaki et al., 2012). 
      Aberrant Notch-Hey1 signaling contributes to Embryonal rhabdomyosarcoma (ERMS) by 
reducing differentiation and promoting proliferation. The efficacy of Notch pathway 
inhibition in vivo supports the development of Notch-Hey1 axis inhibitors in the treatment of 
ERMS (Belyea et al., 2011).  The NOTCH Modulator LNX2 overexpression and 
chromosome 13 amplification therefore constitutively activates the WNT pathway and offers  
evidence of an aberrant NOTCH-WNT axis in Colorectal cancer (CRC) progression (Camps 
et al., 2013). Midkine (MK), a heparin-binding growth factor that is actively overexpressed in 
chemoresistant Pancreatic ductal adenocarcinoma (PDAC) interacts with Notch-2 and  is 
shown to activate Notch signaling, induced EMT, upregulated NF-kβ, and increased chemo 
resistance (Gungor et al., 2011). Gain-of-function mutations in Notch-1 are very common in 
T-cell lymphoblastic leukemia (T-ALL). The proliferation inhibitory and apoptotic effects 
resulting from down-regulation of Notch-1 was expected to be  mediated through regulating 
the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 and the activity of 
Akt signaling in T-cell lymphoblastic leukemia (T-ALL) (Guo et al., 2009). JAG2, a notch 
ligand, overexpression may be an early event in the pathogenesis of multiple myeloma 
involving IL-6 production (Houde et al., 2004). In ovarian cancer Dll4 plays a functionally 
important role in both the tumor and endothelial compartments and targeting Dll4 in 
combination with anti-VEGF treatment can promote outcomes of treatment (Hu et al., 2011). 
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      In another study activating point mutations in NOTCH1 in more than 50% of T-cell acute 
lymphoblastic leukemia (T-ALL) shows that NOTCH1 cascade as a central player of T-ALL 
pathogenesis (Koch and Radtke, 2011). NOTCH signaling is now shown to be pivotal in the 
pathogenesis of a subset of intracranial ependymomas (Pfister and Witt, 2009). Neuralized 
(Neurl) is a highly conserved E3 ubiquitin ligase, which in Drosophila acts upon Notch 
ligands to regulate Notch pathway signaling. Human Neuralized1 (NEURL1) was 
investigated as a potential tumor suppressor in medulloblastoma (MB). NEURL1 is a 
candidate tumor suppressor in MB, at least in part through its effects on the Notch pathway 
(Teider et al., 2010). Jagged1 may be involved in the differentiation and proliferation of 
tongue cancer. Targeting Jagged1 RNA interference by lentiviral vector can effectively lower 
Jagged1 mRNA and protein expression levels in Tca8113 tongue cancer cell lines, thereby 
preventing the proliferation of Squamous cell carcinoma of the tongue (TSCC) cells (Zhang 
et al., 2012). Skeletrophin (mindbomb homolog 2 (MIB2)) is a RING (Really Interesting 
New Gene) finger-dependent ubiquitin ligase, which targets the intracellular region of Notch 
ligands. Exogenously expressed skeletrophin, but not its RING mutant, increased 
transcription of Hes1 gene, a downstream effector of Notch pathway in melanoma cells 
(Stockhausen et al., 2005). Ectopic Myc expression plays a key role in human tumorigenesis 
and Notch signaling downstream of Myc enables cells to adapt in the tumor hypoxic 
microenvironment (Yustein et al., 2010) . 
2. Notch, Epigenetics and Cancer 
     Cancer is both a genetic and an epigenetic disease. Inactivation of tumor-suppressor genes 
by epigenetic changes is frequently observed in human cancers, particularly as a result of the 
modifications of histones and DNA methylation (Ferres-Marco et al., 2006). Epigenetic 
silencers and Notch collaborate to promote malignant tumors by Retinoblastoma (Rb) 
silencing (Ferres-Marco et al., 2006). Two Polycomb group epigenetic silencers, Pipsqueak 
and Lola that participate in this process tumorigenesis were studied in the drosophila eye. 
When coupled with overexpression of Delta, relating to the Notch-Delta pathway, 
deregulation of the expression of Pipsqueak and Lola induces the formation of metastatic 
tumors. This phenotype depends on the histone-modifying enzymes Rpd3 (a histone 
deacetylase), Su(var)3-9 and E(z), as well as on the chromodomain protein Polycomb. 
Expression of the gene Retinoblastoma-family protein (Rbf) is downregulated in these tumors 
and, indeed, this downregulation is associated with DNA hypermethylation (Ferres-Marco et 
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al., 2006). Neuroblastoma cell lines express multiple Notch receptors, which are inactive at 
baseline. Activation of the Notch pathway via ligand binding consistently resulted in growth 
arrest. Hes gene expression here appears to be regulated epigenetically and could be induced 
with decitabine. These findings support a tumor suppressor role for Notch signaling in 
neuroblastoma and also prove its context dependent behavior. In many childhood acute 
leukemias, transcription factors are altered through chromosomal translocations that change 
their functional properties resulting in repressed activity or inappropriate activation. Histone 
deacetylase inhibitors, drugs targeting the NOTCH pathway, and short interfering RNAs have 
shown encouraging results in pre-clinical studies and are likely to enter the clinical arena in 
the near future. Through an improved understanding of the pathways and mechanisms 
underlying the malignant transformation induced by altered transcription factors, new 
targeted epigenetic therapies will be designed that should greatly enhance current available 
treatments (Berman and Look, 2007).  
       The Groucho homologue Transducin-like Enhancer of Split 1 (TLE1) is a transcriptional 
corepressor which acts ill in the acute myelogenous leukemia through Wnt, and Notch 
signaling pathways. The epigenetic inactivation TLE1 contributes significantly to the 
development of the hematologic malignancies by disrupting important pathway of 
differentiation and growth-suppression (Fraga et al., 2008). Dynamic regulation of histone 
modifications is critical during development, and aberrant activity of chromatin-modifying 
enzymes has been associated with diseases such as cancer. The functional interplay between 
histone demethylases in vivo, providing insights into the epigenetic regulation of 
heterochromatin/euchromatin boundaries by Lid and dLsd1 and shows their involvement in 
Notch pathway-specific control of gene expression in euchromatin (Di Stefano et al., 2011). 
Correlation between constitutive acetylation of the JAG2 core promoter in the MM cell lines 
reduced levels of the SMRT corepressor that recruits HDAC to promoter regions. SMRT 
function restoration induced JAG2 down-regulation as well as Multiple myeloma (MM) cell 
apoptosis (Ghoshal et al., 2009).The miR-181c may be silenced through methylation and play 
important roles in gastric carcinogenesis through its target genes, such as NOTCH4 and 
KRAS (Hashimoto et al., 2010). Notch pathway is important in regulating osteosarcoma 
metastasis and may be useful as a epigenetic therapeutic target  of valproic acid and other 
HDAC inhibitors (Hughes, 2009). Epigenetic alterations like DNA methylation and miRNAs 
mediated control of gene expression of multiple Notch target genes and pathway interacting 
genes (PPARG, CCND1, and RUNX1) may relate to activation of this pathway and poor 
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survival of patients with high-grade serous ovarian cancer (HGS-OvCa) (Ivan et al., 2013). 
Epigenetic deregulation of NOTCH4 signaling in OSCC was also observed, as part of a 
possible methylation signature for recurrence, with parallels to recently discovered NOTCH 
mutations in HNSCC (Jithesh et al., 2013).  
      Notch3 is acetylated and deacetylated at lysines 1692 and 1731 by p300 and HDAC1, 
respectively, a balance impaired by HDAC inhibitors (HDACi) that favor hyperacetylation in 
leukemias. Notch signaling control in which Notch3 acetylation/deacetylation process 
represents a key regulatory switch and also a suitable druggable target for Notch3-sustained 
T-cell acute lymphoblastic leukemia therapy (Palermo et al., 2012). Notch1 activity in gastric 
cancer is controlled by the epigenetic silencing of the ligand DLL1, and that Notch1 
inhibition is associated with the diffuse type of gastric cancer (Piazzi et al., 2011). In 
colorectal cancer CRC cell lines, unlike gastric cancer, DLL1 expression is not regulated by 
promoter methylation (Piazzi et al., 2012). Histone deacetylase inhibitor valproic acid is seen 
to be effective by acting on Notch signaling in human neuroblastoma cells.
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                                         OBJECTIVES 
 
The Objectives of our study were: 
1. Determination of the effects of S-Adenosyl Methionine (SAM) and S-
Adenosyl Homocysteine (SAH) on the cellular morphology of breast 
cancer cell line. 
 
2. Role of SAM and SAH in modulation of Notch signaling pathway 
components (Notch-1 and HES-1) in breast cancer. 
 
3. Correlation of Notch signaling components (Notch-1 and HES-1) 
expression and its role in promoting breast cancer cell death. 
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                             MATERIALS AND METHODS 
 
1. Cell lines and culture 
     We obtained the MDA MB-231 cell line from the National Centre for Cell Science 
(NCCS), Pune, India. The cells are known to be of epithelial breast adenocarcinoma origin 
and are triple negative. These were maintained in Dulbecco's modified Eagle's medium 
(DMEM) with 10% fetal bovine serum, 2 mM L-glutamine, and 100 units/ml penicillin-
streptomycin sulfate (Invitrogen). A treatment was carried out with S-Adenosyl methionine 
(SAM) and S-Adenosyl-L-homocysteine (SAH), all purchased from Sigma and added to the 
regular growth media under sterile conditions for 3 days. The media was changed every 24 
well culture plates. 
 
2. MTT Assay 
 
     To determine the proliferative activity, MDA MB-231 cells were seeded in two 96-well 
plates at a density (5000-40,000 cells or 10
6
 cells) based on the doubling time, with 200 μl 
growth media (10% FBS) and incubate for 24 hrs in incubator with 5% CO2 concentration at 
37
o
C. Cell seeding must be uniform in order to obtain a dose response effect of the drug. The 
drug of interests S-Adenosyl Methionine (SAM) and S-Adenosyl Homocysteine (SAH) were 
diluted at 10 different concentrations in the growth media. In parallel the cells with the 
solvent control was also treated to assess its effect on cells. After 24 hours existing media 
was removed and replaced with media with various concentration of drugs and was incubated 
for 24 or 48 hours at 37
o
 C. To detect the cell viability MTT working solution was prepared 
by diluting the stock solution (stock 5mg/ml PBS, PH 7.2)  in growth medium without FBS 
to the final concentration of 0.8mg/ml. 100 μl of MTT working solution was added to each 
well and incubated for 4 hours in CO2 incubator. After incubation, the media was removed 
carefully without disturbing formazan precipitate and dissolved in 100 μl of 100% DMSO. 
An incubation of 15 minutes was carried out in dark and the colorimetric estimation of 
formazan product was performed at 570nm in a microplate reader. The data was plotted 
against drug concentration and non-linear regression curve fitting was performed using graph 
pad prism software to calculate the optimal growth inhibitory concentration (LC50) of the 
drugs. 
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3. Isolation of Total Cellular RNA 
The total cellular RNA was extracted using TRI reagent (Sigma), following the 
manufacturer's instructions. On the culture dish 1 ml of the TRI Reagent per 10 cm
2
 of glass 
culture plate surface area was added. After addition of the reagent, the cell lysate was passed 
several times through a pipette to form a homogenous lysate. TRI Reagent is not compatible 
with plastic culture plates. To ensure complete dissociation of nucleoprotein complexes, 
samples were allowed to stand for 5 minutes at room temperature. 0.1 ml of 1-bromo-3-
chloropropane or 0.2 ml of chloroform was added for per ml of TRI Reagent used. Samples 
were covered tightly, shaken vigorously for 15 seconds, and were allowed to stand for 2–15 
minutes at room temperature. The resulting mixture was centrifuged at 12,000 g for 15 
minutes at 2–8 °C. Centrifugation separates the mixture into 3 phases: a red organic phase 
(containing protein), an interphase (containing DNA), and a colorless upper aqueous phase 
(containing RNA).The aqueous phase was transferred to a fresh tube and 0.5 ml of 
isopropanol was added per ml of TRI Reagent used in Sample Preparation, step 1 and mixed. 
The sample was allowed to stand for 5–10 minutes at room temperature and centrifuged at 
12,000 g for 10 minutes at 2–8 °C. The RNA precipitate formed a pellet on the side and 
bottom of the tube. The supernatant was removed and RNA pellets were washed by adding a 
minimum of 1 ml of 75% ethanol per 1 ml of TRI Reagent used in Sample Preparation. The 
sample was vortexed and then centrifuged at 7,500 ´ g for 5 minutes at 2–8 °C. The RNA 
pellets were briefly dried for 5–10 minutes by air drying.  An appropriate volume of nuclease 
free water was added and mixed by repeated tapping at 25 °C for 10–15 minutes. 
 
4. Quantification of the total cellular RNA 
      Final preparation of RNA was analyzed using a nano-drop UV spectrophotometric 
analyzer. It was likely that a standard preparation of RNA should have a 260/280 ratio of 1.7 
and a 260/230 ratio of <1.65 which indicates the preparation to be free from proteins and 
oligo-peptides contamination. Ethidium bromide (EtBr) staining of RNA in agarose gels 
visualizes two predominant bands of small (2 kb) and large (5 kb) ribosomal RNA, 
low molecular mass (0.1–0.3 kb) RNA, and discrete bands of high molecular mass (7–15 kb) 
RNA. 
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5. cDNA Synthesis and Evaluation 
      In a 1.5 ml tube 5 µl of Deionized RNAse free water, 1 µl of T18- oligo (1 µg), 6 µl of 
dNTPs (10mM), 6 µl of Total RNA (3 µg) were added to make a total volume of  18 µl . The 
tube with the contents was incubated at 65°C for 3 minutes. The tube was snap cooled on ice 
and 6 µl of  Reverse Transcriptase buffer (5X ) ,3 µl  of DTT, 1 µl  of Reverse Transcriptase, 
1 µl  of RNase inhibitor  and 1 µl  of RNase free water the following  added to make  a  total 
volume of the reaction mix 12 µl .The tube was then snap spinned  and incubated at 45 °C for 
45 minutes. Again an incubation at 90 °C for 5 minutes followed up. After incubation a snap 
spin was carried out and 30 µl of deionized water was added. The cDNA prepared can now 
be used immediately or can be stored at -30 °C.  The synthesized cDNA was evaluated by 
performing PCR for one of the house keeping genes such as β-actin. PCR reaction mix was 
prepared with 5.0 µl of 10X Taq polymerase buffer, 2.5 µl of 10mM dNTP mix, 1.5 µl of 1.5 
mM MgCl2, 2.0 µl of Oligo (mActin- Forward) 10 µM, 2.0 µl of Oligo (mActin- Reverse) 10 
µM, 1.0 µl   of Taq DNA polymerase and 26.0 µl of deionized water to make a total volume 
of 40.0 µl. Two aliquots of 20 µl of PCR mix was transferred into 2 PCR tubes. 5 µl of 
cDNA was added in one tube and 5 µl deionized water was added in another. The tubes were 
snap spinned to collect the contents in the bottom of the tubes and were subject to PCR with 
the following cycling conditions of ; 92° C for 3 minutes, 30 cycles of 92 °C 30 sec, 50 °C 
for 30 sec, 72 °C for 30 sec, 72 °C for 5 minutes and  4 °C for forever. The contents were 
loaded in 1.5% agarose gel and electrophoresed along with a molecular weight marker. The 
gel was visualized under UV light and results were documented in a gel documentation 
system. 
6. RT-PCR Analysis 
      We used total RNA (2 μg.) isolated from the cancerous cell lines for reverse transcription 
and amplification. The primers used for RT-PCR were designed so that there is an intron 
between the amplified regions to recognize any DNA contamination. We used three sets of 
primers to amplify NOTCH1, HES-1 and β-actin genes having sequence as detailed in Table 
no.  for each RNA sample. The PCR were carried out using standard protocols and the DNA 
was amplified under the following conditions: 95 °C for 3 min, 30 cycles of 95 °C for 30 s, 
60 °C for 30 s, and 72 °C for 30 s, and the final extension of 72 °C for 5 min. We then 
analyzed the PCR products on a 1% agarose gel. 
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Table. 1 Primers used for RT-PCR Analysis 
Serial 
No. 
Primer Name Sequence Scale (uM) Purification Length 
1 Notch1 Forward  primer 5'CCGCCTTTGTGCTTCTGTT3' 0.025 DST 19 
2 Notch1 Reverse  primer 5'TCCTCCTCTTCCTCGCTGTT3' 0.025 DST 20 
3 HES1 Forward  primer 5'ATGGAGAAAAATTCCTCGTCCC3' 0.025 DST 22 
4 HES1 Reverse  primer 5'TTCAGAGCATCCAAAATCAGTGT3' 0.025 DST 23 
5 β –ACTIN Forward 5’CTGGAACGGTGAAGGTGACA3’ 0.025 DST 20 
6 β -ACTIN Reverse 5’AAGGGACTTCCTGTAACAACGCA3’ 0.025 DST 23 
 
7. Study of change in cellular morphology by Scanning Electron 
Microscopy (SEM)     
     Cells on attaining 70% confluence on 0.2% gelatin precoated 10-mm coverslips in 35-mm 
petri dishes were cultured. Dishes without treatment were used as controls and were kept for 
the same period of induction using suitable growth media. After 24 and 48 hours of drug 
treatment with S-Adenosyl methionine (SAM) and S-Adenosyl-L-homocysteine (SAH), the 
dishes containing the coverslips with cells were used for SEM analysis. In preliminary 
experiments, differentiated adipocytes were detached and lipid was extracted by normal 
fixation and dehydration procedures used for SEM .Treatment medium from the dishes was 
decanted and the cells were fixed with freshly prepared 2.5% glutaraldehyde in DPBS at 4 °C 
for 3 h. The dishes with fixed cells were washed twice with DPBS and dehydrated with 
methanol. It was also found that the fixed cells could be stored in DPBS at 4 °C for a 
maximum of 1 week and dehydrated when necessary. Stored dishes were brought to room 
temperature and again washed once with DPBS. Coverslips with dishes were then dried in 
vacuum-assisted desiccators overnight and then stored at room temperature till SEM analysis 
was carried out. The surface of the coverslip was sputter-coated in a vacuum with an 
electrically conductive 5 nm thick layer of Platinum Precession Etching Coating system. 
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SEM images were then recorded with a scanning electron microscope at a lower voltage (20 
kV) and low vacuum mode with a tilt of 30°. 
8. Cell migration assay (Scratch assay) 
 
      60-mm dishes were coated with proper ECM substrates for the cell type to be studied by 
incubating the dishes overnight at 4 °C or for 2 h at 37 °C without rotation or shaking. The 
unbound ECM substrate was removed and dishes were blocked and coated with 3 ml of 2 mg 
ml-1 bovine serum albumin for 1 h at 37°C. Then the dishes were once washed with PBS and 
refilled with 3–5 ml of media before plating the cells. For the particular cell type used, the 
appropriate amount of serum in the medium during the in vitro scratch assay is required to be 
determined. It is always recommended to use a lower percentage of serum than that used in 
the growth media to minimize cell proliferation, but just sufficient to prevent apoptosis and/or 
cell detachment. Sub-confluent growing cells were re-suspended in a tissue culture dish by 
washing cells twice with PBS, adding versene containing trypsin, and then mixing cells with 
medium containing serum. The solution was gently pipetted and the dish was rocked to 
disperse the cells equally. An aliquot from the cell suspension was taken and the cell count 
was determined using a hemocytometer. Cells were plated onto the prepared 60-mm dish to 
create a confluent monolayer and incubated properly for approximately 6 hours at 37°C, 
allowing cells to adhere and spread on the substrate completely. The required number of cells 
for a confluent monolayer depends on both the particular cell type and the size of dishes and 
need to be adjusted appropriately. The cell monolayer was scraped in a straight line to create 
a „„scratch‟‟ with a p200 pipet tip.  
 
      The debris was removed and the edge of the scratch was smoothed by washing the cells 
once with 1 ml of the growth medium and then replaced with 5 ml of medium specific for the 
in vitro scratch assay. To obtain the same field during the image acquisition markings were 
created to be used as reference points close to the scratch. The reference points can be made 
by etching the dish lightly with a razor blade on the outer bottom of the dish or with an 
ultrafine tip marker. After the reference points were made, the dish was placed under a phase-
contrast microscope, and reference mark was left outside the capture image field but within 
the eye-piece field of view. The first image of the scratch was taken. The dish was placed in a 
tissue culture incubator at 37°C for 8–18 hours. After the incubation dish was placed under a 
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phase-contrast microscope, the reference point was matched; the photographed region was 
aligned to acquire a second image. 
 
 
9. Analysis of chromatin condensation by Hoechst 33342 stain 
 
    After treatment with drugs, the cells were stained with Hoechst 33342 stain (1 mg/ml) and 
incubated for 10 min at 37°C and images were taken under UV filter using Epi-fluorescent 
Microscope (Nikon TE 2000E). Condensed nucleus was counted against total number of 
nucleus in the field, and the percentages of apoptotic nuclei were analyzed. 
 
10. Cytochemical staining of for detecting autophagosomes  
    An optimal number of cells were seeded based on doubling time in a 96 well plate and kept 
for 24 hours in incubator with 5% CO2 at 37°C.  After the incubation period, the cells were 
challenged with the suspected autophagy modulating factor for 12 hours. Then after 
incubation, the existing media was removed and 100µl of fresh media containing 1µg/ml of 
acridine orange was added. The cells were incubated for 15min at normal culture 
conditions. The media was discarded and washed with PBS and fresh media was added to the 
cells. The cells were analyzed under a fluorescent microscope using blue filter (495nm) to 
view the green fluorescence (510-530nm) from free Acridine Orange and red fluorescence (> 
650nm) from acidic vesicles (autophagosomes).  
11. Comet assay to measure the DNA damage 
 
    Two water baths were equilibrated at 40 °C and 100 °C respectively. Than 1% low-gelling-
temperature agarose was prepared by mixing powdered agarose with distilled water in a glass 
beaker or bottle. The bottle was placed in the 100 °C water bath for several minutes and was 
transferred into a 40 °C water bath. Agarose-precoated slides were prepared by dipping the 
slides into molten 1% agarose and wiping one side clean. It is best to work in a low-humidity 
environment to ensure agarose adhesion. Agarose was allowed to air-dry to a thin film. Slides 
can be prepared ahead of time and stored with desiccant. A single-cell suspension was 
prepared using enzyme disaggregation or mechanical dissociation. The cells were kept in ice-
cold medium or phosphate-buffered saline to minimize cell aggregation and inhibit DNA 
repair. Using a hemocytometer or particle counter, cell density was adjusted to about 2 × 104 
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cells/ml in phosphate-buffered saline lacking divalent cations. Slides were labeled on frosted 
end using a pencil. 0.4 ml of cells into a 5 ml plastic disposable tube.1.2 ml 1% low-gelling-
temperature agarose at was added at 40 °C.1.2 ml of cell suspension onto the agarose-covered 
surface of a pre-coated slide was mixed by vigorous pipetting. Agarose was allowed to be gel 
for about 2 min. After agarose has gelled, slides were submerged in a covered dish containing 
A1 lysis solution. Samples were lysed overnight (18−20 h) at 4 °C in the dark. After 
overnight lysis, slides were removed carefully and submerge in A2 rinse solution for 20 min 
at room temperature (18−25 °C). The process was repeated two times to ensure removal of 
salt and detergent. Care was taken for not allowing DNA to renature even briefly (i.e., by 
lowering pH below 12.3) until after electrophoresis, as this will result in DNA tangling and 
reduced migration. After these three rinses, slides were submerged in fresh A2 solution in an 
electrophoresis chamber. The chamber was filled with a consistent volume of buffer that is 
about 1–2 mm above the top of the agarose. It was ensured that the chamber is level using a 
bubble leveling device. Electrophoresis was conducted in solution A2 for 25 min at a voltage 
of 0.6 V/cm. The current was about 40 mA using 20 V. The distance in centimeters was 
measured between the negative and positive electrodes in the electrophoresis chamber. Slides 
were removed from electrophoresis chamber and were rinsed and neutralized in 400 ml of 
distilled water. Slides were placed in staining solution containing 2.5 μg/ml of propidium 
iodide in distilled water for 20 min. Finally the slides were rinsed with 400 ml distilled water 
to remove excess stain. Analysis of cells was done by examining at least 50 comet images 
from each slide. Analyzing doublets or comets at slide edges should be avoided. 
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                            RESULTS AND DISCUSSION 
 
1. Cell viability assay by MTT Method 
 
      MDA MB -231 cell viability was determined after SAM and SAH treatment by MTT 
Assay. The IC50 value for both the drugs was calculated. Both the SAM and SAH treatment 
showed decrease in cell viability but SAM treatment showed little higher decrease in cell 
viability. 
 
              
      Fig 7. Graphical analysis of cell viability after SAM and SAH treatment 
 
2. Isolation of Total Cellular RNA by Trizol Method 
     The total cellular RNA isolated was isolated following the manufacturer‟s  instructions 
by Tri-reagent (Sigma).The isolation of the RNA was carried out from the cultured cells of 
the wells of the six well plates from two wells in a time dependent manner of 24 hours  and 
48 hours. The isolation was almost pure and in good yield as the reading in Nano drop 
spectrophotometer showed the 260/280 absorption ratio above 1.7 and the 260/230 
absorption ratio above 1.65 for all the samples quantified.  
                                                                                                              Results & Discussion 2013 
 
 
29 
3. cDNA Synthesis and RT-PCR  
     Previous studies and the RT-PCR data confirmed that Notch1 and HES1 were up 
regulated in breast cancer cell line MDA-MB 231. A time dependent treatment with S-
Adenosyl Methionine (SAM) for 24hours and 48 hours showed down regulation of these 
components but similar treatment with S-Adenosyl Homocysteine (SAH) showed the up 
regulation of these components. 
 
   
Fig 8. Graphical representation of RT-PCR results for expression level of Notch1 after SAM 
and SAH   treatment 
           
Fig 9. Graphical representation of RT-PCR results for expression level of HES1 after SAM and 
SAH   treatment 
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4.  Study of change in cellular morphology by Scanning Electron 
Microscopy (SEM) 
      After treatment of the MDA MB-231 cells with SAM and SAH in a time dependent 
manner for 24 and 48 hours the change in the cellular morphology was observed by a 
Scanning Electron Microscope. The images suggested that there was a change in the normal 
cellular morphology of MDA MB-231 cells as they started to attain a round shape suggesting 
an induction of a mechanism like apoptosis. But in the SAH treated cells there was no such 
significant change in the cellular morphology. 
       
Fig 10.  SEM images showing changes in cellular morphology after SAM and SAH treatment 
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5. Cell migration study by Scratch assay 
 
      For the study of migratory property of the MDA MB-231 cells after SAM and SAH 
treatment for 0-48hr in a time dependent manner the scratch assay was performed .The results 
showed that there was more migration of cells towards the scratched area in SAH treated 
cells as compared to the SAM treated in comparison with the untreated plates taken as control 
in a time dependent manner.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 11.  Microscopic images showing changes in the migratory property of MDA MB-231 cells 
after SAM and SAH treatment 
Untreated  0 hr. Untreated  24 hrs. Untreated  48 hrs. 
SAH  0 hr. SAH 24 hrs. SAH  48 hrs. 
SAM  0 hr. 
hrs. 
SAM  24  hrs. SAM 48 hrs. 
                                                                                                              Results & Discussion 2013 
 
 
32 
6. Analysis of chromatin condensation by Hoechst 33342 stain 
    After treatment with SAM and SAH for 0-48hr in a time dependent manner the MDA-MB-
231 cells were stained with Hoechst 33342 stain and analyzed for the chromatin 
condensation. The results indicated that there was formation of more condensed chromatin 
structures after treatment with SAM than SAH in a time dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 12. Fluorescence microscopic condensed chromatin images showing after SAM and SAH    
treatment 
SAM 24 hr. SAM 48 hr. 
SAH 24 hr. SAH 48 hr. 
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7. Cytochemical staining for detecting autophagosomes 
     The MDA MB-231 cells after the formation of the treatment with SAM and SAH for 24-
48 hr. in a time dependent manner were analyzed for the formation of autophagosomes. The 
SAM treated cells showed greater frequency in the formation of autophagosomes after a 
treatment of 48 hours. But the SAH treatment was found less efficient in forming the 
autophagic vesicles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 13.  Fluorescence microscopic images showing formation of autophagosomes after SAM and 
SAH    treatment 
SAM (24hrs) 
SAH( 48 hrs.) 
SAM (48 hrs.) 
SAH( 24 hrs.) 
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8. DNA damage measured by Comet Assay 
     MDA MB-231 cells in culture after treatment with SAM and SAH for 24-48 hr. in a time 
dependent manner were analyzed for the amount of DNA damage by the comet assay. The 
results showed significant amount of DNA damage in SAM treatment as compared to SAH 
and the untreated control cells. The characteristic comet tail length suggested the amount of 
DNA damaged. In SAM treatment the cells were seen to be having a more dispersed tail as 
compared to the tails of the SAH treated cells and the control untreated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 14.  Fluorescence microscopic images showing DNA damage after SAM and SAH    
treatment
    SAM 24 hr.     SAM 48 hr. 
SAH 48 hr.     SAH 24 hr. 
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                                           CONCLUSION 
 
      Work over the last decade has shown that Notch signaling is aberrantly activated in breast 
cancer and that it regulates many of the cellular properties associated with transformation. 
This has led to significant interest in the use of Notch pathway inhibitors for breast cancer 
treatment, especially as they are expected to have effects in bulk tumor cells, cancer stem 
cells and the surrounding tumor stroma. The question now is how best to use these inhibitors 
in clinical trials. Current preclinical work indicates that Notch pathway inhibitors are unlikely 
to be effective on their own, but that they should significantly increase the efficacy of current 
therapies. This said, there is still a need to identify patients that are likely to respond to Notch 
pathway inhibitors (He et al. 2011; Watters et al. 2009). From our study we found that after 
treating the MDA MB-231 metastatic breast cancer cell line with epigenetic modulators SAM 
and SAH  , the Notch signaling components Notch1 and Hes1 are down regulated after SAM 
treatment and were significantly upregulated after SAH treatment. This was accompanied by 
changes in cellular phenotypes of the cells as the SAM treatment changed the cells to more 
round shape, Reduced migratory potential , Induced autophagosome formation , Aggravated 
chromatin condensation , Caused DNA damage as compared to SAH treated cells. 
    From these above experimental results we can tentatively conclude that SAM treatment of 
invasive breast cancer cell line induced cell death in a notch dependent manner. This 
experimental data suggests that SAM can be a potent therapeutic agent for treatment of breast 
cancer.
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